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p53 is dynamically regulated through various post-
translational modifications (PTMs), which differen-
tially modulate its function and stability. The dime-
thylated marks p53K370me2 and p53K382me2 are
associated with p53 activation or stabilization and
both are recognized by the tandem Tudor domain
(TTD) of 53BP1, a p53 cofactor. Here we detail
the molecular mechanisms for the recognition
of p53K370me2 and p53K382me2 by 53BP1. The
solution structures of TTD in complex with the
p53K370me2 and p53K382me2 peptides show a
remarkable plasticity of 53BP1 in accommodating
these diverse dimethyllysine-containing sequences.
We demonstrate that dimeric TTDs are capable
of interacting with the two PTMs on a single
p53K370me2K382me2 peptide, greatly strength-
ening the 53BP1-p53 interaction. Analysis of binding
affinities of TTD toward methylated p53 and histones
reveals strong preference of 53BP1 for p53K382me2,
H4K20me2, and H3K36me2 and suggests a possible
role of multivalent contacts of 53BP1 in p53 targeting
to and accumulation at the sites of DNA damage.
INTRODUCTION
The tumor suppressor p53 is mutated in nearly half of all human
cancers, and most of the remaining cancers are associated with
decreased p53 levels or alterations in p53-mediated signaling
pathways (Brosh and Rotter, 2009; Cheok et al., 2011; Levine
and Oren, 2009; Muller and Vousden, 2013). p53 is a transcrip-
tion factor involved in the regulation of over 100 genes essential
in cell cycle control, senescence, DNA damage repair, and
apoptosis (Vousden and Lane, 2007). Owing to its rapid degra-
dation, the constitutive concentration of p53 in resting cells is
maintained at a relatively low level. However, in response to
DNA damage or other stress signals, p53 becomes activated
and triggers growth arrest, followed by DNA damage repair or
induces apoptosis if the damage cannot be repaired. Transcrip-312 Structure 23, 312–321, February 3, 2015 ª2015 Elsevier Ltd All rtional activity, nuclear accumulation, stability, and translocation
of p53 are mediated by multiple posttranslational modifications
(PTMs), including phosphorylation, acetylation, methylation,
ubiquitination, SUMOylation, and neddylation (Dai and Gu,
2010; Zhang et al., 2012). The PTMs are especially abundant in
the C-terminal regulatory domain (CTD) of p53, which contains
multiple modifiable lysine, serine, and threonine residues.
Four lysine residues, K370, K372, K373, and K382, in the p53
CTD tail are currently known to undergo methylation (Chuikov
et al., 2004; Huang and Berger, 2008; Huang et al., 2006,
2007, 2010; Kachirskaia et al., 2008; Shi et al., 2007) (Figure 1A).
Methylation was originally thought to influence p53 stability
and function by competing for the same lysine residues that
can be acetylated or ubiquitinated. It is now well established
that monoubiquitination of lysines leads to p53 translocation
from the nucleus to the cytoplasm, polyubiquitination targets
p53 for proteasomal degradation, and acetylation increases
p53 stability and occupancy at promoters of p53 target genes
(Dai and Gu, 2010). Several pioneering reports have demon-
strated that methylation marks in the CTD tail have an effect on
transcriptional and transcription-independent functions of p53
(Chuikov et al., 2004; Huang and Berger, 2008; Huang et al.,
2006, 2007, 2010; Kachirskaia et al., 2008; Shi et al., 2007).
These PTMs can alter the structure, dynamics, and ability of
p53 to interact with various binding partners and mediate p53
commitment to a particular pathway within a large p53-depen-
dent signaling network.
The biological outcome of CTD methylation can lead to p53
activation or suppression, depending on the PTM position and
the extent of methylation, i.e. the number of methyl groups
attached to the ε-amino moiety of the lysine. Monomethylation
of K372 by the lysine methyltransferase 7 (KMT7), also known
as SET7/9, stabilizes p53 at chromatin and facilitates transcrip-
tion of p53 target genes (Chuikov et al., 2004). In contrast, mono-
methylation of either K370 by KMT3C (Smyd2) or K382 by
KMT5A (SET8/PR-SET7) suppresses p53 transactivation (Huang
et al., 2006, 2007; Shi et al., 2007; West et al., 2010), and dime-
thylation of K373 by homologous KMT1C/D (G9a/Glp) also
correlates with inactive p53 (Huang et al., 2010).
The dimethylated marks p53K370me2 and p53K382me2
have been identified in vivo and biochemically characterized
in vitro, although methyltransferases responsible for writing
these PTMs remain unknown (Huang et al., 2007; Kachirskaiaights reserved
Figure 1. The Solution Structure of the Tandem Tudor Domain (TTD)
of 53BP1 in Complex with a p53K370me2 Peptide
(A) Schematic representation of the domain architecture of p53 and 53BP1.
BRCT, BRCA1 carboxy-terminal repeats; CTD, C-terminal domain; DBD,
DNA-binding domain; Olig, oligomerization domain; TA, transactivation
domain; TET, tetramerization domain; TTD, tandem Tudor domain.
(B and C) The structure of the TTD–p53K370me2 complex. TTD is depicted as
a solid surface (B) and a ribbon diagram (C), with the peptide shown as a yellow
ribbon. The TTD residues that form an aromatic cage around dimethylated
K370 and those involved in the polar interactions with the peptide are colored
salmon and wheat, respectively. p53K370me2 residues are labeled in yellow
and TTD residues are labeled in black. Dashed lines represent intermolecular
hydrogen bonds, see also Figures S1–S3.et al., 2008). Cellular levels of these PTMs increase in response
to DNA damage, and p53K370me2 and p53K382me2 have
been simultaneously detected in stressed and unstressed cells
by mass spectrometry, although it remains unclear whether
these marks are present on the same p53 molecule (DeHart
et al., 2014). p53K370me2 positively regulates p53 transcrip-
tional activity and can be demethylated to a repressiveStructure 23, 31p53K370me1 mark by lysine specific demethylase 1, whereas
p53K382me2 is associated with p53 stability and accumulation
at DNA double-strand breaks (DSBs) (Huang et al., 2007; Kachir-
skaia et al., 2008). Both p53K382me2 and p53K370me2 are
recognized by the tandem Tudor domain (TTD) of p53-binding
protein 1 (53BP1) (Figure 1A) (Huang et al., 2007; Kachirskaia
et al., 2008). Interaction of the TTD module with p53K382me2
plays a role in p53 stabilization at DSBs and binding to
p53K370me2 is essential for p53 transactivation uponDNAdam-
age (Huang et al., 2007; Kachirskaia et al., 2008). 53BP1 is a key
DNA damage responsemediator and a coactivator of p53, which
also recognizes methylated histones, H4K20me2 particularly, as
well as dimethylated at K810 retinoblastoma protein and DNA
(Botuyan et al., 2006; Carr et al., 2014; Charier et al., 2004; Huyen
et al., 2004; Kim et al., 2006). Recent studies have shown that the
association of 53BP1 TTD with H4K20me2 is necessary but not
sufficient to rapidly recruit 53BP1 to damaged DNA. Such
recruitment requires oligomerization of 53BP1 through its oligo-
merization domain, located upstream of the TTD (Fradet-Tur-
cotte et al., 2013; Ward et al., 2006; Zgheib et al., 2009), and
ubiquitination of histone H2A (Fradet-Turcotte et al., 2013). The
pairing of TTDs via 53BP1 oligomerization raises the possibility
for a mechanistic and functional crosstalk between multiple di-
methyllysine substrates, including PTMs on p53 and histones.
Here we describe the molecular basis for binding of the 53BP1
TTD module to p53K370me2 and p53K382me2. Nuclear mag-
netic resonance (NMR) structures of the complexes reveal a
remarkable plasticity of 53BP1 in accommodating these diverse
dimethyllysine-containing sequences. Analyses of binding affin-
ities and specificities indicate that 53BP1 can simultaneously
recognize dual K370me2/K382me2 marks on a single p53 sub-
strate and suggest a model for rapid accumulation of p53 at
DSBs that involves multiple interactions of oligomeric 53BP1
with p53, H4K20me2, and H3K36me2.
RESULTS AND DISCUSSION
p53K370me2 Is Bound in a Deep Cleft of 53BP1 TTD
To elucidate the mechanism for the recognition of p53K370me2,
we determined the solution structure of 53BP1 TTD in complex
with a p53K370me2 peptide (residues R363–T377 of p53). We
previously attempted to crystallize the p53K370me2-TTD com-
plex (Roy et al., 2010); however, electron density seen only for
the K370me2 residue of the peptide precluded analysis of the
binding mechanism and prompted us to obtain the structure us-
ing NMR spectroscopy. The solution structure of the
p53K370me2-bound TTD shows a canonical fold of the domain,
consisting of the tandem five-stranded b barrels linked by a
C-terminal a helix (Figures 1B and 1C; Table 1; Figures S1 and
S2 available online). The NMR assemble also reveals an exten-
sive protein–peptide interface of 707 ± 43 A˚2.
The amino-terminal residues of the p53 peptide, H365-S371,
occupy a long, deep cleft at the Tudor1–Tudor2 border (Fig-
ure S1). From a total of 68 intermolecular nuclear Overhauser en-
hancements (NOEs), 66 signals involve these residues of p53.
The centrally positioned p53 L369 lies in a hydrophobic cavity
created by the Y1500, L1547, Y1520,M1554, and I1587 residues
of the protein (Figure S2). L369 contributes 31 intermolecular
NOEs (13 with Y1502, 6 with L1547, 5 with Y1500, 3 with2–321, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 313
Table 1. NMR and Refinement Statistics
NMR Distance and
Dihedral Restraints
53BP1 TTD–
p53K370me2
53BP1 TTD–
p53K382me2
Distance Restraints
Total NOE 4,243 4,099
Intraresidue 889 848
Interresidue 3,286 3,212
Sequential (ji  jj = 1) 850 822
Medium range (ji  jj < 5) 722 697
Long range(ji  jj > 4) 1,714 1,693
Intermolecular 68 39
Hydrogen bonds 65 65
Total Dihedral Angle
Restraints
226 226
f 76 78
j 77 77
c1 73 71
Additional Distance Constraints
Crystallography-based
restraintsa
15 15
Structure Statistics
Violations (mean ± SD)
Distance constraints (A˚) 0.10 ± 0.02 0.08 ± 0.04
Dihedral angle constraints () 2.67 ± 0.96 1.82 ± 1.02
Maximum dihedral
angle violation ()
4.46 3.77
Maximum distance
restraint violation (A˚)
0.16 0.20
Deviations from Idealized Geometry
Bond lengths (A˚) 0.0080 ± 0.0001 0.0081 ± 0.0001
Bond angles () 2.08 ± 0.02 2.83 ± 0.24
Impropers () 0.23 ± 0.01 1.67 ± 0.33
Average Pairwise Root-Mean-Square Deviation (A˚)b
Heavy 0.94 ± 0.09 1.11 ± 0.12
Backbone 0.50 ± 0.07 0.64 ± 0.11
aAdditional distance restraints involving K370me2 and K382me2 were
derived from crystal structures of these complexes.
bCalculated from residues 1488–1603 of 53BP1, residues 365–371 of
p53K370me2, and residues 379–385 of p53K382me2.M1584, 2 with I1587, 1 with E1549, and 1 with E1551). In the
crystal structure of p53K370me2-bound TTD, the side chain
of K370me2 inserts in the aromatic cage formed by the four
aromatic residues, W1495, Y1502, F1519, and Y1523, and a
negatively charged aspartate, D1521 (Roy et al., 2010). The
aromatic moieties make favorable hydrophobic and cation-p
contacts with the dimethylammonium group of p53 K370, and
the carboxylate of D1521 forms a hydrogen bond with the
only amino proton and a salt bridge with the ion. Two NOEs
detected between K370me2 and the aromatic cage residues
and the chemical shift perturbations (CSPs) at the 53BP1–
p53K370me2 interface are fully consistent with K370me2
occupying the aromatic cage in the solution structure (see
Experimental Procedures; Figure S2B).314 Structure 23, 312–321, February 3, 2015 ª2015 Elsevier Ltd All rThe side chains of p53 H368 and S371 are well restrained by
15 and 8 intermolecular NOEs, respectively. The tandem lysine
residues p53 K372 and p53 K373 are solvent exposed and
the carboxyl-terminal residues p53 G374–T377 are relatively
flexible (Figure S2). Overall, a number of polar, electrostatic,
and hydrophobic interactions of the TTD with p53K370me2
unambiguously position the p53 peptide in such a manner that
the N terminus of the peptide is bound near the b3–b4 loop of
Tudor1 and the b6–b7 loop of Tudor2, whereas the C terminus
of p53 is oriented toward the a helix of the TTD.
We examined the contribution of the potential intermolecular
hydrogen bonding and hydrophobic contacts to complex forma-
tion by comparing CSPs in 1H,15N heteronuclear single quantum
coherence (HSQC) spectra of 15N-labeled TTD bound to
p53KC370me2 peptides. In these peptides, K370 was replaced
with a dimethyllysine analog (N-dimethylated aminoethylcys-
teine, KC370me2), whereas other residues were individually
substituted with a flexible glycine (Figure S3). Alterations in
CSPs induced by p53H365GKC370me2, p53H368GKC370me2,
and p53L369GKC370me2 peptides confirmed the important
role of the buried H365, H368, and L369 residues for the interac-
tion with TTD. However, the solvent-exposed K372 and K373
appear to be dispensable, as p53KC370me2K372G and
p53KC370me2K373G peptides caused the same CSPs as the
wild-type p53KC382me2 peptide.
p53K382me2 Is Bound in a U-shape Conformation
To obtain molecular insight into the recognition of p53K382me2,
we determined the solution structure of 53BP1 TTD bound to the
p53K382me2 peptide (residues S376–T387 of p53) (Table 1). The
NMR assemble shows a large protein–peptide interface of 678 ±
60 A˚2. Unexpectedly, we found that in the complex, the
p53K382me2 peptide adopts a U-shape conformation and binds
in the orientation that is opposite to the orientation of the
p53K370me2 peptide (Figure 2). In contrast to p53K370me2,
the N terminus of the p53K382me2 peptide is positioned near
the second b barrel, and we were unable to superimpose the
structures of the two peptides in the bound states.
Much like dimethylated K370 of the p53K370me2 peptide, di-
methylated K382 of p53K382me2 lies in the aromatic cage of the
TTD; however, the rest of the peptide residues are bound differ-
ently (Figure 2A). The carboxyl group of TTD E1551 forms a salt
bridge with the guanidino group of p53 R379. Four intermolec-
ular NOEs position p53 H380 in the vicinity of Y1500, F1553,
L1547, and I1587. The conformation of p53 K381 is fixed through
four NOEs to Y1500 and three NOEs to Y1502. The side chains of
L383 and F385 contact a hydrophobic groove formed by the
Y1502, L1547, M1584, and I1587 residues of the TTD. Fifteen
NOEs are seen between these TTD residues and p53 L383,
whereas the aromatic ring of F385 is constrained via seven inter-
molecular NOEs with the TTD residues L1547, I1587, M1584,
and Y1523 (Figure S2). The side chains of p53 M384 and p53
K386 appear to be unrestrained.
Comparative analysis of CSPs produced in the TTD by
glycine mutants of p53KC382me2 peptide revealed the impor-
tant role of the p53 residues adjacent to the dimethyllysine,
such as R379, H380, K381, L383, and F385 (Figure S3).
NMR titration experiments showed that among eight mutant
peptides tested, p53R379GKC382me2, p53H380GKC382me2,ights reserved
Figure 2. The Solution Structure of the 53BP1 TTD in Complex with a
p53K382me2 Peptide
(A and B) TTD is depicted as a solid surface (A) and a ribbon diagram (B),
with the peptide shown as an orange ribbon. The TTD residues that form an
aromatic cage around dimethylated K382 and those involved in the polar
interactions with the peptide are colored salmon and wheat, respectively.
p53K382me2 residues are labeled in orange and TTD residues are labeled
in black. Dashed lines represent intermolecular hydrogen bonds, see also
Figures S2 and S3.p53K381GKC382me2, p53KC382me2L383G, and p53KC382
me2F385G altered the pattern of CSPs caused by the wild-
type p53KC382me2 peptide, indicating that the R379, H380,
K381, L383, and F385 residues significantly contribute to the
interaction with TTD. These data were in agreement with previ-
ous findings that the replacement of H380 and K381 with an
alanine reduces binding of the TTD 16-fold and 11-fold,
respectively (Roy et al., 2010).
An alignment of methyllysine-containing p53 CTD and histone
tail sequences shows a high degree of similarity between
p53K382me2 and H4K20me2, which may imply a comparable
binding mechanism (Figure 3A). The overlaid NMR structures
of the peptides derived from the TTD-p53K382me2 and TTD-
H4K20me2 (Tang et al., 2013) complexes demonstrate that
although both peptides are oriented in a similar manner, the
overall binding modes differ (Figure 3B). Our results point to a
high plasticity of 53BP1 TTD in accommodating the dimethylly-
sine substrates. Furthermore, such an intricate recognition of
each of the p53K370me2, p53K382me2, and H4K20me2
sequences suggests that the TTD can distinguish between dime-
thyllysine marks (see below). It also suggests a possibility ofStructure 23, 31generating distinct mutations in 53BP1 TTD that impair binding
to a particular dimethyllysine ligand. Interestingly, the hybrid
Tudor domains of JMJD2A (KDM4A) have previously been found
to recognize histone H3K4me3 and H4K20me3 peptides using
different binding mechanisms (Lee et al., 2008).
We note that the same p53 peptide acetylated at K382
(p53K382ac) has been shown to bind in a remarkably similar
U-shape conformation to a bromodomain of CBP, a structurally
unrelated module (Mujtaba et al., 2004), implying that the
p53K382 region may prefer this bound-state conformation,
irrespective of the nature of PTM on K382 (Figure 3C).
The First but not the Second b Barrel of 53BP1
TTD Is Functional
A thorough mass spectrometry analysis of PTMs on p53 has
shown the coexistence of p53K370me2 and p53K382me2 in hu-
man foreskin fibroblasts treated with a DNA damage-inducing
agent, etoposide, as well as in the untreated cells (DeHart
et al., 2014). Although it remains unclear if both marks are
present on the same p53 molecule, previous observations that
cellular levels of these PTMs increase in response to DNA dam-
age suggest that they may (Huang et al., 2007; Kachirskaia et al.,
2008). Furthermore, the two sequential single Tudor domains of
PHF20 have been shown to form a dimer, which could associate
with the p53 CTD dimethylated at K370 and K382 (Cui et al.,
2012). We examined the ability of the 53BP1 TTD to bivalently
interact with p53K370me2K382me2. Structural analysis of the
53BP1 complexes reveals that the TTD folds into two almost
identical b barrels, with the dimethyllysine substrate being
bound in the aromatic cage of the first b barrel. As the second
b barrel also contains a cluster of aromatic residues, we
tested whether each b barrel is capable of accommodating
a dimethyllysine PTM. Of note, the distance (20 A˚) between
the aromatic patches of the TTD is ideal for the interaction with
p53K370me2K382me2 (Figures 4A and 4B). We generated the
p53K370me2K382me2 peptide using solid-phase peptide syn-
thesis and tested it in NMR and fluorescence spectroscopy
assays.
Titration of the p53K370me2K382me2 peptide into 15N-
labeled 53BP1 TTD resulted in large CSPs in 1H,15N HSQC
spectra of the protein (Figure 4C). Plotting CSPs for each TTD
residue and mapping the most significant changes onto the
TTD structure revealed that the aromatic cage of the first b barrel
of TTD is substantially perturbed (Figures 4D and 4E). However,
the aromatic patch of the second b barrel was essentially unaf-
fected, implying that only the first but not the second b barrel
of the TTD is functional (Figures 4C–4E). This is in striking
contrast to the homodimeric Tudor domains of PHF20, each of
which associates with dimethylated p53 (Cui et al., 2012).
Notably, the binding pocket of the second b barrel of 53BP1
TTD is basic in nature, whereas the binding pocket of the first
b barrel is acidic (Figure S4). Electrostatic repulsion of a posi-
tively charged methyllysine may contribute to the inability of
the second b barrel to accommodate this PTM. The intermediate
exchange regime on the NMR chemical shift timescale for the
interaction of the TTD with p53K370me2K382me2 indicated a
stronger binding in comparison with binding to the singly modi-
fied peptides, due to an increase in local concentration of the
dimethyllysine ligand in p53K370me2K382me2 (Figure 4C).2–321, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 315
Figure 3. Recognition of the Dimethyllysine Sequences by the 53BP1 TTD
(A) Alignment of the p53 and histone H3 and H4 sequences with dimethylated lysine residues highlighted in orange. Moderately and weakly conserved residues
are colored green and blue.
(B) Structural overlay of the p53K382me2 peptide (orange) bound to TTD and the H4K20me2 peptide (gray) bound to TTD (PDB 2LVM). TTD is not shown.
(C) Structural overlay of the p53K382me2 peptide (orange) bound to TTD and the p53K382ac peptide (gray) bound to a bromodomain of CBP (PDB 1JSP). TTD
and the bromodomain are not shown.Thus, we concluded that although the 53BP1 TTD binds better to
the proximate methylation PTMs on p53, it utilizes only the aro-
matic cage of the first b barrel to do so.
Dimeric TTDs Bind Robustly to p53K370me2K382me2
Oligomerization of 53BP1 links multiple TTDs, making it possible
for 53BP1 to simultaneously associate with several methyllysine
targets. To mimic the oligomerization-mediated pairing of TTDs
and to examine whether the linked modules are capable of
concurrent binding to p53K370me2K382me2, we generated a
longer 53BP1 construct, consisting of residues 1481–1603 and
incorporated a cysteine residue at the N terminus. In this
construct, native cysteine residues 1525 and 1535weremutated
to alanines. The purified 15N-labeled protein was chemically
crosslinked to form an N terminus to N terminus homodimer
(CL-TTD) using bismaleimide and then separated from the
monomeric form by chromatography (Figure 5A; Figure S5). A
comparison of the 1H,15N HSQC spectrum of CL-TTD with that
of TTD revealed several additional peaks, likely belonging to
the linker residues, and a few resonance changes, most of which
were clustered around the points of alanine mutations of
the native cysteine residues (Figure 5B). The lack of significant
differences in chemical shifts and limited changes in the line
widths suggested a full flexibility of the crosslinked domains.
Addition of the singly modified p53K382me2 peptide to uni-
formly 15N-labeled CL-TTD caused substantial chemical shift
changes in the protein (Figure 5C). The pattern of CSPs indicated
that both crosslinked domains bind to the methylated peptide in
a manner similar to the binding of a single TTD. However, upon
titration of the doubly methylated p53K370me2K382me2 pep-
tide, many peaks in the 1H,15N HSQC spectra of CL-TTD broad-
ened and disappeared (Figure 5C, third panel). Particularly, the
CL-TTD residues located in and around themethyllysine-binding
pocket in the first b barrel showed a significant decrease in
intensity (Figure S5). The overall decrease in cross-peak intensity
implied a decrease in flexibility of the two TTDs and/or the
formation of a larger, slow tumbling complex, and thus sug-
gested that the CL-TTD associates with both PTMs on a single316 Structure 23, 312–321, February 3, 2015 ª2015 Elsevier Ltd All rp53K370me2K382me2 peptide. In agreement, binding of an
equimolar mixture of the p53K370me2 and p53K382me2
peptides to the CL-TTD failed to produce a large complex, as
no significant change in resonance intensities was observed
(Figure 5C, second panel).
The ability of CL-TTD to bivalently associate with the
p53K370me2K382me2 peptide was substantiated through
measuring binding affinities. Analysis of the binding curves of
CL-TTD in fluorescence assays required a two-site-binding
model and yielded Kd values of 0.1 mM and 17 mM, indicating
that both linked TTDs were involved in the interaction with the
peptide (Figure 6A; Figure S5). The increase in affinity of the
linked TTDs compared with binding affinities of the individual
TTDs is likely entropically driven, as both TTDs and dimethylated
PTMs are prealigned for the interaction. Furthermore, the
dimeric glutathione S-transferase (GST)-fused TTD, in which
the two TTD molecules are ideally oriented for concurring inter-
actions with the double PTMs, bound to the p53K370me
2K382me2 peptide stronger (Kd values of 0.01 mM and 2.6 mM)
(Figure S5E).
Models for the Bivalent Interactions of 53BP1 TTDs
Generally, oligo(di)merization of 53BP1 can promote binding of
the TTD either to multiple dimethyllysine marks on a single pep-
tide (in cis), or to dimethyllysine PTMs on multiple proteins
(in trans). Modeling of the p53K370me2-TTD and p53K382me2-
TTD complexes suggests that p53K370me2K382me2 can hold
a pair of TTDs in a sequential manner, with the avidity effect
enhancing this association (Figure 6B).
Alternatively, the linked TTDs could bridge dimethylated p53
with dimethylated histone tails. It was previously reported that
53BP1 TTD binds to H4K20me2 (Botuyan et al., 2006) and
weakly associates with some other dimethylated histones (Bo-
tuyan et al., 2006; Huyen et al., 2004; Kim et al., 2006); however,
a comprehensive analysis of the TTD substrates has not been
performed. To establish the 53BP1 TTD specificity, we designed
an extensive library of peptides containing known PTMs on
core and variant histones and on the p53 CTD (Table S1) andights reserved
Figure 4. The First b Barrel of the 53BP1
TTD Is Functional
(A) Possible bivalent interactions of TTD.
(B) The 53BP1 TTD is shown as a ribbon diagram,
with the dimethyllysine (green) bound in the aro-
matic cage of the first b barrel. The aromatic
pockets of Tudor1 and Tudor2 are outlined.
(C) Superimposed 1H,15N HSQC spectra of TTD
collected upon titration with the indicated p53
peptides. Spectra are color coded according to
the protein/peptide molar ratio (see inset).
(D) The normalized chemical shift changes
observed in 1H,15N HSQC spectra of TTD upon
titration with p53K370me2K382me2 peptide as
a function of residue.
Residues showing large chemical shift differences
are mapped onto the structure of TTD in (E), see
also Figure S4.examined binding of GST-tagged 53BP1 TTD (Figure 6C).
Screening GST-TTD against the library showed that among
the p53 peptides tested, the protein recognized primarily
p53K382me2, and to a lesser degree p53K370me2. These
data corroborated well the Kd values of 0.9 mM and 20 mM,
measured for the interactions of TTD with p53K382me2 and
p53K370me2, respectively (Roy et al., 2010) (Figure 6A). The
peptide library screening also confirmed a robust binding to his-
tone H4K20me2 (Kd = 1.3 mM) (Botuyan et al., 2006; Roy et al.,
2010) (Figure 6C). Unexpectedly, we detected a strong interac-
tion of the 53BP1 TTD with H3K36me2. Binding to H3K18me2
wasweaker, andmuchweaker associations with other dimethyl-
lysine-containing histone peptides, including H3K79me2, were
observed. To further verify the peptide library data, wemeasured
the binding affinity of the TTD for H3K36me2 using tryptophan
fluorescence. The Kd value was found to be 1.5 mM, which
is comparable with the affinity of TTD for p53K382me2 and
H4K20me2 (Figure 6A). The pattern of CSPs in 1H,15N HSQC
spectra of the TTD induced by H3K36me2 peptide suggested
that dimethylated K36 occupies the aromatic cage (Figure S6).
These results demonstrate that the 53BP1 TTD module has a
strong preference toward the p53K382me2, H4K20me2, and
H3K36me2 sequences.Structure 23, 312–321, February 3, 2015Concluding Remarks
The discovery of numerous PTMs on
p53 reveals a complex signaling network
that resembles the histone code phe-
nomenon (Strahl and Allis, 2000), yet the
biological significance of the p53 methyl-
lysine marks and their relationship with
histone PTMs remain largely unexplored.
In this study, we determined the mole-
cular mechanisms for the recognition
of p53K382me2 and p53K370me2 by
the TTD module of a p53 coactivator,
53BP1. 53BP1 is a mediator and effector
of the DSB response that plays a central
role in DNA damage repair (Panier and
Boulton, 2014). We also found that the
53BP1 TTD has a strong preference forp53K382me2, H4K20me2, and H3K36me2, and this selectivity
suggests a possible role of multivalent contacts in 53BP1 local-
ization and activity.
DNA damage triggers an acute mobilization of 53BP1 to DSB
sites, and both oligomerization of 53BP1 and binding of the
TTD to H4K20me2 are required for the efficient recruitment of
53BP1 (Botuyan et al., 2006; Fernandez-Capetillo et al., 2002;
Fradet-Turcotte et al., 2013; Huyen et al., 2004; Kachirskaia
et al., 2008; Rappold et al., 2001; Roy et al., 2010; Zgheib
et al., 2009). However, H4K20me2 is a highly abundant PTM,
which is ubiquitously present in the majority (>80%) of nucleo-
somes in mammalian cells (Panier and Boulton, 2014).
H4K20me2 is generated independently of DNA damage and
therefore cannot instigate a specific focal recruitment of 53BP1
to DNA lesions (Panier and Boulton, 2014), whereas
H3K36me2 can. The H3K36me2 levels increase considerably
at the DSB sites following DNA damage (Fnu et al., 2011; Jha
and Strahl, 2014; Pai et al., 2014). H3K36me2 recruits and stabi-
lizes components of the DNA repair machinery, and installation
of this PTMhas been shown to be amajor immediatemethylation
event at DSBs, which also correlates with the DNA repair effi-
ciency (Fnu et al., 2011; Musselman et al., 2012a). DNA damage
raises p53K382me2 levels as well (Kachirskaia et al., 2008).ª2015 Elsevier Ltd All rights reserved 317
Figure 5. Crosslinked TTDs Bind to
p53K370me2K382me2
(A) Possible oligomerization-mediated bivalent
interactions of TTD.
(B) An overlay of 1H,15N HSQC spectra of TTD
(black) and CL-TTD (red).
(C) Superimposed 1H,15N HSQC spectra of CL-
TTD collected upon titration with the indicated
p53 peptides, see also Figure S5.Accordingly, oligomerized 53BP1 could concurrently associate
with p53K382me2 and H3K36me2, recruiting p53 to DSBs.
Binding of the TTD to the abundant H4K20me2 and the associ-
ation of a short neighboring region with H2A ubiquitinated at
K15 (Fradet-Turcotte et al., 2013) can stabilize 53BP1 at
damaged DNA, contributing to anchoring or retention of
53BP1. Other methyllysine marks, including p53K370me2,
which is also generated in response to DNA damage (Huang
et al., 2007), may aid in the p53-53BP1-chromatin assembly by
enhancing avidity of oligomeric 53BP1. This mechanism of rapid
accumulation and stabilization of 53BP1/p53 could be critical in
the early response to DNA damage; however, further studies will
be necessary to fully explore it.
EXPERIMENTAL PROCEDURES
Protein and Peptide Expression, Purification, and Crosslinking
The wild-type TTD of human 53BP1 (residues 1484–1603 and 1481–1603)
was expressed and purified as reported previously (Botuyan et al., 2006;
Roy et al., 2010). The C1525A/C1535A mutant of the 1481–1603 TTD was
generated by site-directed mutagenesis using the Stratagene QuikChange
Mutagenesis protocol. To generate a crosslinked TTD, a Cys residue
was added to the N terminus of the C1525A/C1535A construct. The TTD
was crosslinked at room temperature for 2 hr in PBS using bismaleimido-
ethane (Thermo Scientific Pierce). Monomer and crosslinked homodimer
were separated using a Superdex 75 10/300 GL Tricorn column (GE Life
Sciences).
The p53K370me2 (residues 363–377) and p53K382me2 (residues 376–
387) peptides were chemically synthesized and purified by reversed-phase
high-performance liquid chromatography. To allow 13C and 15N isotope
enrichment for NMR spectroscopy experiments, the p53 peptides were
also produced in Escherichia coli as a fusion to an N-terminal GB1–hexahis-
tidine tag cleavable by TEV protease, chemically modified to install a dime-
thylated lysine analog (KC370me2 or KC382me2 with and without
13C
enrichment of the two methyl groups) and purified by size exclusion and318 Structure 23, 312–321, February 3, 2015 ª2015 Elsevier Ltd All rights reservedreversed-phase chromatography, as reported
previously (Cui et al., 2009). The recombinant
peptides include three N-terminal expression
vector-encoded residues (Gly-His-Met). The
p53K370me2K382me2 peptide (residues S366–
K386) was synthesized by 9-fluorenylmethoxy-
carbonyl solid-phase peptide synthesis using
an Applied Biosystem 431A peptide synthesizer,
as described (Roy et al., 2010).
Solution Structures of the TTD-
p53K370me2 and TTD-p53K382me2
Complexes
The NMR experiments were recorded at 298 K
using a Bruker Avance 700 MHz spectrometer
equipped with a cryoprobe. Protein samples
were made in 25 mM sodium phosphate
(pH 7.5), 90% H2O/10% D2O or 100% D2O
and 1.5 mM NaN3. Different samples were pre-pared for complex resonance assignments and structure determination.
These are 2 mM 13C/15N-labeled 53BP1 TTD and 6 mM nonlabeled
p53K370me2 (or p53K382me2), and 2 mM 13C/15N-labeled p53KC370me2
and 5 mM nonlabeled 53BP1 TTD. Because of difficulties producing the
p53Kc382me2 peptide from expression in E. coli, a low concentration com-
plex of 0.5 mM 13C/15N-labeled p53KC382me2 and 2 mM nonlabeled 53BP1
TTD was prepared and used only to facilitate resonance assignment. No
intermolecular NOEs were measured from this sample. A combination of
2D 1H-15N HSQC, 1H-13C HSQC and 3D HNCA, HNCACB, CBCA(CO)NH,
HNCO, HN(CA)CO, (H)CC(CO)NH, H(CC)(CO)NH, HBHA(CO)NH, 15N-
TOCSY-HSQC, and (H)CCH-TOCSY experiments were used for 53BP1
TTD backbone and side-chain assignments. 2D 1H-13C HSQC and 3D
13C-NOESY HSQC optimized for aromatic resonances as well as 2D (HB)
CB(CGCD)HD were collected to assign 53BP1 TTD aromatic ring reso-
nances. 2D 1H-13C HSQC and 3D (H)CCH-TOCSY and 13C-NOESY HSQC
were recorded to assign p53KC370me2 resonances.
13C/15N double-filtered
13C-edited 3D NOESY HSQC spectra (Zwahlen et al., 1997) were recorded
to identify intermolecular NOEs. The NOE signals were assigned through
several iterations of CYANA (version 2.1) (Gu¨ntert, 2004) and SANE (Duggan
et al., 2001) calculations. For the initial structure calculations, we used
only intermolecular NOEs corresponding to easily identifiable signals from
53BP1 TTD and the p53 peptides, such as NOEs involving the methyl
groups of 53BP1 TTD and p53 (Mer et al., 2000). Through multiple iterations,
we were able to manually assign a total of 68 intermolecular NOEs for
the 53BP1 TTD–p53K370me2complex. For the 53BP1 TTD–p53K382me2
complex, a total of 39 intermolecular NOEs were assigned. Because of
exchange broadening and signal disappearance for residues in the 53BP1
aromatic cage, only two NOEs involving p53 residue K370me2 were
detected (K370 HB# and 53BP1 Y1502 HD#) and none for p53K382me2.
For the structure calculation, we therefore included 15 distance restraints
derived from the crystal structures of 53BP1 TTD in complex with
p53K370me2 and p53K382me2 (Roy et al., 2010) to position the side
chain of K370me2 and K382me2. The NMR data were processed using
NMRPipe (Delaglio et al., 1995) and analyzed using NMRView (Johnson
and Blevins, 1994).
The interproton distances derived from signal integration of the NOESY
spectra were classified into five categories, corresponding to a lower
Figure 6. Bivalent Interactions of the 53BP1
TTDs
(A) Affinities of TTD and CL-TTD as determined by
tryptophan fluorescence spectroscopy. *Taken
from (Roy et al., 2010).
(B) Modeling the bivalent association of CL-TTD
with p53K370me2K382me2 using the structures
of TTD in complex with p53K382me2 and
p53K370me2 and the structure of p53 peptide.
(C) Effects of the indicated PTMs on the binding
of the 53BP1 TTD to histone and p53 peptides.
Results of four arrays are presented as normalized
mean intensities. Error bars represent SEM from
pooled averages. Dotted lines demarcate groups
of peptides with conserved sequence, see also
Figure S6 and Table S1.distance limit of 1.8 A˚ and upper limits of 2.8, 3.5, 4.5, 5.5, and 7.5 A˚. The
upper limit of 7.5 A˚ was used only for very weak signals, which could be
due to spin diffusion. Distance restraints corresponding to hydrogen bonds
identified from 1H/2D exchange experiments were also included with upper
limits of 3.2 A˚ and 2.2 A˚ for N–O and HN–O, respectively. Dihedral angle
restraints 4 and c were derived from TALOS (Cornilescu et al., 1999) and
chemical shift index (Wishart and Sykes, 1994) analysis and included in the
calculations with a tolerance of ± 30. c1 angle restraints were based on
NOE intensity analysis and, likewise, were included in the calculations,
with a tolerance of ±30.
Two hundred structures were calculated using CYANA, of which the
100 structures with lowest energies were refined by simulated annealing
using AMBER (Case et al., 2005), with inclusion of the generalized Born
solvation model (Tsui and Case, 2000). The force constants were
20 kcal mol1 A˚2 for NOE-derived distance restraints, 40 kcal mol1
A˚2 for hydrogen bond-derived distance restraints, 50 kcal mol1 rad2
for dihedral angle restraints, 100 kcal mol1 rad2 for chirality restraints,
and 150 kcal mol1 rad2 for omega angle restraints. The 20 structures
with the lowest AMBER energies and lowest dihedral angle violations
were retained for the final analysis. The quality of the final structures
was assessed using PROCHECK-NMR. The structural statistics are pro-
vided in Table 1.Structure 23, 312–321, February 3, 2015NMR Titration Experiments
1H,15N HSQC spectra were collected at 298 K on
0.1–0.2 mM uniformly 15N-labeled TTD or CL-TTD
on a Varian INOVA 600-MHz spectrometer equip-
ped with a cryogenic probe. Binding was charac-
terized by monitoring chemical shift changes as
differently modified p53 peptides or H3K36me2
peptide were added stepwise.
Fluorescence Spectroscopy
Tryptophan fluorescence measurements were re-
corded on a Fluoromax-3 spectrofluorometer
(HORIBA) at room temperature. The samples con-
taining 0.2–0.5 mMCL-TTD, GST-TTD, or TTD and
progressively increasing concentrations of the di-
methylated p53 or histone peptides were excited
at 295 nm. Emission spectra were recorded from
305 to 405 nm with a 0.5 nm step size and a 1 s
integration time, averaged over three scans. The
Kd values were determined as described (Mussel-
man et al., 2009, 2012b). The Kd values were aver-
aged over three separate experiments, with the
error calculated as the SD between runs.
Peptide Microarray
Peptide synthesis and validation, microarray
fabrication, effector protein hybridization anddetection, and data analysis were performed as previously described
(Gatchalian et al., 2013).ACCESSION NUMBERS
Atomic coordinates for the structures have been deposited in the Protein
Data Bank (PDB) under accession codes 2MWO and 2MWP for 53BP1-TTD-
p53K370me2 and 53BP1-TTD-p53K382me2, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.str.2014.11.013.
AUTHOR CONTRIBUTIONS
Q.T., G.C., G.M., and T.G.K. designed the study. Q.T., G.C., M.V.B., and
S.B.R. performed experiments and together with R.H., C.A.M., N.S., E.A.,
B.D.S., G.M., and T.G.K. analyzed the data. T.G.K. wrote the manuscript
with input from all authors.ª2015 Elsevier Ltd All rights reserved 319
ACKNOWLEDGMENTS
This research is supported by grants from the NIH, GM101664 (T.G.K.),
CA132878 (G.M.), GM110058 (B.D.S.) and CA181343 (S.B.R.). G.M. acknowl-
edges partial support from the Mayo Clinic SPORE NCI grants P50CA116201
and P50CA108961. This research is also supported in part by the Intramural
Research Program of the Center for Cancer Research, National Cancer Insti-
tute, NIH (EA).
Received: June 30, 2014
Revised: November 11, 2014
Accepted: November 13, 2014
Published: January 8, 2015
REFERENCES
Botuyan, M.V., Lee, J., Ward, I.M., Kim, J.E., Thompson, J.R., Chen, J., and
Mer, G. (2006). Structural basis for the methylation state-specific recognition
of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 127, 1361–1373.
Brosh, R., and Rotter, V. (2009). When mutants gain new powers: news from
the mutant p53 field. Nat. Rev. Cancer 9, 701–713.
Carr, S.M., Munro, S., Zalmas, L.P., Fedorov, O., Johansson, C., Krojer, T.,
Sagum, C.A., Bedford, M.T., Oppermann, U., and La Thangue, N.B. (2014).
Lysinemethylation-dependent binding of 53BP1 to the pRb tumor suppressor.
Proc. Natl. Acad. Sci. USA 111, 11341–11346.
Case, D.A., Cheatham, T.E., 3rd, Darden, T., Gohlke, H., Luo, R., Merz, K.M.,
Jr., Onufriev, A., Simmerling, C., Wang, B., andWoods, R.J. (2005). The Amber
biomolecular simulation programs. J. Comput. Chem. 26, 1668–1688.
Charier, G., Couprie, J., Alpha-Bazin, B., Meyer, V., Quemeneur, E., Guerois,
R., Callebaut, I., Gilquin, B., and Zinn-Justin, S. (2004). The Tudor tandem of
53BP1: a new structural motif involved in DNA and RG-rich peptide binding.
Structure 12, 1551–1562.
Cheok, C.F., Verma, C.S., Baselga, J., and Lane, D.P. (2011). Translating p53
into the clinic. Nat. Rev. Clin. Oncol. 8, 25–37.
Chuikov, S., Kurash, J.K., Wilson, J.R., Xiao, B., Justin, N., Ivanov, G.S.,
McKinney, K., Tempst, P., Prives, C., Gamblin, S.J., et al. (2004). Regulation
of p53 activity through lysine methylation. Nature 432, 353–360.
Cornilescu, G., Delaglio, F., and Bax, A. (1999). Protein backbone angle re-
straints from searching a database for chemical shift and sequence homology.
J. Biomol. NMR 13, 289–302.
Cui, G., Botuyan, M.V., and Mer, G. (2009). Preparation of recombinant pep-
tides with site- and degree-specific lysine (13)C-methylation. Biochemistry
48, 3798–3800.
Cui, G., Park, S., Badeaux, A.I., Kim, D., Lee, J., Thompson, J.R., Yan, F.,
Kaneko, S., Yuan, Z., Botuyan, M.V., et al. (2012). PHF20 is an effector protein
of p53 double lysine methylation that stabilizes and activates p53. Nat. Struct.
Mol. Biol. 19, 916–924.
Dai, C., and Gu, W. (2010). p53 post-translational modification: deregulated in
tumorigenesis. Trends Mol. Med. 16, 528–536.
DeHart, C.J., Chahal, J.S., Flint, S.J., and Perlman, D.H. (2014). Extensive
post-translational modification of active and inactivated forms of endogenous
p53. Mol. Cell Proteomics 13, 1–17.
Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. (1995).
NMRPipe: a multidimensional spectral processing system based on UNIX
pipes. J. Biomol. NMR 6, 277–293.
Duggan, B.M., Legge, G.B., Dyson, H.J., and Wright, P.E. (2001). SANE
(Structure Assisted NOE Evaluation): an automated model-based approach
for NOE assignment. J. Biomol. NMR 19, 321–329.
Fernandez-Capetillo, O., Chen, H.T., Celeste, A., Ward, I., Romanienko, P.J.,
Morales, J.C., Naka, K., Xia, Z., Camerini-Otero, R.D., Motoyama, N., et al.
(2002). DNA damage-induced G2-M checkpoint activation by histone H2AX
and 53BP1. Nat. Cell Biol. 4, 993–997.
Fnu, S., Williamson, E.A., De Haro, L.P., Brenneman, M., Wray, J., Shaheen,
M., Radhakrishnan, K., Lee, S.H., Nickoloff, J.A., and Hromas, R. (2011).320 Structure 23, 312–321, February 3, 2015 ª2015 Elsevier Ltd All rMethylation of histone H3 lysine 36 enhances DNA repair by nonhomologous
end-joining. Proc. Natl. Acad. Sci. USA 108, 540–545.
Fradet-Turcotte, A., Canny, M.D., Escribano-Diaz, C., Orthwein, A., Leung,
C.C., Huang, H., Landry, M.C., Kitevski-LeBlanc, J., Noordermeer, S.M.,
Sicheri, F., and Durocher, D. (2013). 53BP1 is a reader of the DNA-damage-
induced H2A Lys 15 ubiquitin mark. Nature 499, 50–54.
Gatchalian, J., Futterer, A., Rothbart, S.B., Tong, Q., Rincon-Arano, H.,
Sanchez de Diego, A., Groudine, M., Strahl, B.D., Martinez, A.C., van Wely,
K.H., and Kutateladze, T.G. (2013). Dido3 PHD modulates cell differentiation
and division. Cell Rep. 4, 148–158.
Gu¨ntert, P. (2004). Automated NMR structure calculation with CYANA.
Methods Mol. Biol. 278, 353–378.
Huang, J., and Berger, S.L. (2008). The emerging field of dynamic lysine
methylation of non-histone proteins. Curr. Opin. Genet. Dev. 18, 152–158.
Huang, J., Perez-Burgos, L., Placek, B.J., Sengupta, R., Richter, M., Dorsey,
J.A., Kubicek, S., Opravil, S., Jenuwein, T., and Berger, S.L. (2006).
Repression of p53 activity by Smyd2-mediated methylation. Nature 444,
629–632.
Huang, J., Sengupta, R., Espejo, A.B., Lee, M.G., Dorsey, J.A., Richter, M.,
Opravil, S., Shiekhattar, R., Bedford, M.T., Jenuwein, T., and Berger, S.L.
(2007). p53 is regulated by the lysine demethylase LSD1. Nature 449, 105–108.
Huang, J., Dorsey, J., Chuikov, S., Zhang, X., Jenuwein, T., Reinberg, D., and
Berger, S.L. (2010). G9a and Glp methylate lysine 373 in the tumor suppressor
p53. J. Biol. Chem. 285, 9636–9641.
Huyen, Y., Zgheib, O., Ditullio, R.A., Jr., Gorgoulis, V.G., Zacharatos, P., Petty,
T.J., Sheston, E.A., Mellert, H.S., Stavridi, E.S., and Halazonetis, T.D. (2004).
Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand
breaks. Nature 432, 406–411.
Jha, D.K., and Strahl, B.D. (2014). An RNA polymerase II-coupled function for
histone H3K36 methylation in checkpoint activation and DSB repair. Nat.
Commun. 5, 3965.
Johnson, B.A., and Blevins, R.A. (1994). NMR View: a computer program for
visualization and analysis of NMR data. J. Biomol. NMR 4, 603–614.
Kachirskaia, I., Shi, X., Yamaguchi, H., Tanoue, K., Wen, H., Wang, E.W.,
Appella, E., and Gozani, O. (2008). Role for 53BP1 Tudor domain recognition
of p53 dimethylated at lysine 382 in DNA damage signaling. J. Biol. Chem.
283, 34660–34666.
Kim, J., Daniel, J., Espejo, A., Lake, A., Krishna, M., Xia, L., Zhang, Y., and
Bedford, M.T. (2006). Tudor, MBT and chromo domains gauge the degree of
lysine methylation. EMBO Rep. 7, 397–403.
Lee, J., Thompson, J.R., Botuyan, M.V., and Mer, G. (2008). Distinct binding
modes specify the recognition of methylated histones H3K4 and H4K20 by
JMJD2A-tudor. Nat. Struct. Mol. Biol. 15, 109–111.
Levine, A.J., and Oren, M. (2009). The first 30 years of p53: growing ever more
complex. Nat. Rev. Cancer 9, 749–758.
Mer, G., Bochkarev, A., Gupta, R., Bochkareva, E., Frappier, L., Ingles, C.J.,
Edwards, A.M., and Chazin, W.J. (2000). Structural basis for the recognition
of DNA repair proteins UNG2, XPA, and RAD52 by replication factor RPA.
Cell 103, 449–456.
Mujtaba, S., He, Y., Zeng, L., Yan, S., Plotnikova, O., Sachchidanand,
Sanchez, R., Zeleznik-Le, N.J., Ronai, Z., and Zhou, M.M. (2004). Structural
mechanism of the bromodomain of the coactivator CBP in p53 transcriptional
activation. Mol. Cell 13, 251–263.
Muller, P.A., and Vousden, K.H. (2013). p53mutations in cancer. Nat. Cell Biol.
15, 2–8.
Musselman, C.A., Mansfield, R.E., Garske, A.L., Davrazou, F., Kwan, A.H.,
Oliver, S.S., O’Leary, H., Denu, J.M., Mackay, J.P., and Kutateladze, T.G.
(2009). Binding of the CHD4 PHD2 finger to histone H3 is modulated by cova-
lent modifications. Biochem. J. 423, 179–187.
Musselman, C.A., Avvakumov, N., Watanabe, R., Abraham, C.G., Lalonde,
M.E., Hong, Z., Allen, C., Roy, S., Nunez, J.K., Nickoloff, J., et al. (2012a).
Molecular basis for H3K36me3 recognition by the Tudor domain of PHF1.
Nat. Struct. Mol. Biol. 19, 1266–1272.ights reserved
Musselman, C.A., Ramirez, J., Sims, J.K., Mansfield, R.E., Oliver, S.S., Denu,
J.M., Mackay, J.P., Wade, P.A., Hagman, J., and Kutateladze, T.G. (2012b).
Bivalent recognition of nucleosomes by the tandem PHD fingers of the
CHD4 ATPase is required for CHD4-mediated repression. Proc. Natl. Acad.
Sci. USA 109, 787–792.
Pai, C.C., Deegan, R.S., Subramanian, L., Gal, C., Sarkar, S., Blaikley, E.J.,
Walker, C., Hulme, L., Bernhard, E., Codlin, S., et al. (2014). A histone
H3K36 chromatin switch coordinates DNA double-strand break repair
pathway choice. Nat. Commun. 5, 4091.
Panier, S., and Boulton, S.J. (2014). Double-strand break repair: 53BP1 comes
into focus. Nat. Rev. Mol. Cell Biol. 15, 7–18.
Rappold, I., Iwabuchi, K., Date, T., and Chen, J. (2001). Tumor suppressor p53
binding protein 1 (53BP1) is involved in DNA damage-signaling pathways.
J. Cell Biol. 153, 613–620.
Roy, S., Musselman, C.A., Kachirskaia, I., Hayashi, R., Glass, K.C., Nix, J.C.,
Gozani, O., Appella, E., and Kutateladze, T.G. (2010). Structural insight into
p53 recognition by the 53BP1 tandem Tudor domain. J. Mol. Biol. 398,
489–496.
Shi, X., Kachirskaia, I., Yamaguchi, H., West, L.E., Wen, H., Wang, E.W., Dutta,
S., Appella, E., and Gozani, O. (2007). Modulation of p53 function by SET8-
mediated methylation at lysine 382. Mol. Cell 27, 636–646.
Strahl, B.D., and Allis, C.D. (2000). The language of covalent histone modifica-
tions. Nature 403, 41–45.
Tang, J., Cho, N.W., Cui, G., Manion, E.M., Shanbhag, N.M., Botuyan, M.V.,
Mer, G., and Greenberg, R.A. (2013). Acetylation limits 53BP1 association
with damaged chromatin to promote homologous recombination. Nat.
Struct. Mol. Biol. 20, 317–325.Structure 23, 31Tsui, V., and Case, D.A. (2000). Theory and applications of the generalized
Born solvation model in macromolecular simulations. Biopolymers 56,
275–291.
Vousden, K.H., and Lane, D.P. (2007). p53 in health and disease. Nat. Rev.
Mol. Cell Biol. 8, 275–283.
Ward, I., Kim, J.E., Minn, K., Chini, C.C., Mer, G., and Chen, J. (2006). The
tandem BRCT domain of 53BP1 is not required for its repair function. J. Biol.
Chem. 281, 38472–38477.
West, L.E., Roy, S., Lachmi-Weiner, K., Hayashi, R., Shi, X., Appella, E.,
Kutateladze, T.G., and Gozani, O. (2010). The MBT repeats of L3MBTL1 link
SET8-mediated p53 methylation at lysine 382 to target gene repression.
J. Biol. Chem. 285, 37725–37732.
Wishart, D.S., and Sykes, B.D. (1994). The 13C chemical-shift index: a simple
method for the identification of protein secondary structure using 13C chem-
ical-shift data. J. Biomol. NMR 4, 171–180.
Zgheib, O., Pataky, K., Brugger, J., and Halazonetis, T.D. (2009). An oligomer-
ized 53BP1 tudor domain suffices for recognition of DNA double-strand
breaks. Mol. Cell Biol. 29, 1050–1058.
Zhang, X., Wen, H., and Shi, X. (2012). Lysine methylation: beyond histones.
Acta Biochim. Biophys. Sin. (Shanghai) 44, 14–27.
Zwahlen, C., Legault, P., Vincent, S.J.F., Greenblat, J., Konrat, R., and Kay,
L.E. (1997). Methods of measurements of intermolecular NOEs bymultinuclear
NMR spectroscopy: application to a bacteriophage N-peptide/box B RNA
complex. J. Am. Chem. Soc. 119, 6711–6721.2–321, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 321
